SG11202001806TA - Treatment method - Google Patents

Treatment method

Info

Publication number
SG11202001806TA
SG11202001806TA SG11202001806TA SG11202001806TA SG11202001806TA SG 11202001806T A SG11202001806T A SG 11202001806TA SG 11202001806T A SG11202001806T A SG 11202001806TA SG 11202001806T A SG11202001806T A SG 11202001806TA SG 11202001806T A SG11202001806T A SG 11202001806TA
Authority
SG
Singapore
Prior art keywords
treatment method
treatment
Prior art date
Application number
SG11202001806TA
Inventor
Derek Nigel John Hart
Georgina Jane Clark
Edward Alan Abadir
Xinsheng Ju
Ziduo Li
Original Assignee
Kira Biotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017903726A external-priority patent/AU2017903726A0/en
Application filed by Kira Biotech Pty Ltd filed Critical Kira Biotech Pty Ltd
Publication of SG11202001806TA publication Critical patent/SG11202001806TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
SG11202001806TA 2017-09-13 2018-09-12 Treatment method SG11202001806TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017903726A AU2017903726A0 (en) 2017-09-13 Treatment method
PCT/AU2018/050987 WO2019051541A1 (en) 2017-09-13 2018-09-12 Treatment method

Publications (1)

Publication Number Publication Date
SG11202001806TA true SG11202001806TA (en) 2020-03-30

Family

ID=65722240

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001806TA SG11202001806TA (en) 2017-09-13 2018-09-12 Treatment method

Country Status (10)

Country Link
US (1) US20200277396A1 (en)
EP (1) EP3681536A4 (en)
JP (1) JP2020533384A (en)
KR (1) KR20200066613A (en)
CN (1) CN111565749A (en)
AU (2) AU2018333275A1 (en)
CA (1) CA3074379A1 (en)
MX (1) MX2020002702A (en)
SG (1) SG11202001806TA (en)
WO (1) WO2019051541A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2951208B1 (en) 2013-02-01 2019-11-13 Kira Biotech Pty Limited Anti-cd83 antibodies and use thereof
US20200108098A1 (en) * 2018-02-23 2020-04-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Anti-cd83 chimeric antigen receptor expressing t regulatory cells
WO2021258140A1 (en) * 2020-06-23 2021-12-30 Kira Biotech Pty Limited Cd83 binding protein conjugates for treating lymphoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2951208B1 (en) * 2013-02-01 2019-11-13 Kira Biotech Pty Limited Anti-cd83 antibodies and use thereof
CN105899535A (en) * 2013-12-17 2016-08-24 豪夫迈·罗氏有限公司 Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
AU2015336931B2 (en) * 2014-10-23 2021-04-29 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
MX2017005751A (en) * 2014-11-03 2018-04-10 Genentech Inc Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment.

Also Published As

Publication number Publication date
CA3074379A1 (en) 2019-03-21
AU2022204077A1 (en) 2022-06-30
CN111565749A (en) 2020-08-21
EP3681536A4 (en) 2021-06-09
KR20200066613A (en) 2020-06-10
MX2020002702A (en) 2020-10-05
US20200277396A1 (en) 2020-09-03
EP3681536A1 (en) 2020-07-22
WO2019051541A1 (en) 2019-03-21
JP2020533384A (en) 2020-11-19
AU2018333275A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
GB201701109D0 (en) Method
GB2567616B (en) Treatment method
GB201811679D0 (en) Treatment apparatus
GB2571601B (en) Treatment method
GB201706406D0 (en) Method of treatment
IL281792A (en) Treatment methods
GB201815588D0 (en) Method of treatment
GB201700352D0 (en) Method
SG11202001806TA (en) Treatment method
IL281839A (en) Treatment methods
GB201702250D0 (en) Method
EP3597225A4 (en) Treatment method
IL254336A0 (en) Novel treatment method
IL270867A (en) Treatment method
SG11202004923XA (en) Sterilization method
SG10201913377VA (en) Treatment apparatus
GB201702096D0 (en) Method
GB201701941D0 (en) Method
GB201718985D0 (en) Treatment
GB201713650D0 (en) Treatment
GB201720439D0 (en) Method of treatment
GB201718589D0 (en) Method of treatment
AU2017903726A0 (en) Treatment method
GB201706955D0 (en) Treatment